<DOC>
	<DOC>NCT01167881</DOC>
	<brief_summary>This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.</brief_summary>
	<brief_title>Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: Diagnosis typ 2 diabetes mellitus Male and female on diet and exercise regimen, pretreated with metformin 12 weeks prior to randomisation HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1 18 years or more BMI equal or less than 45Kg/m2 Exclusion criteria: Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight fast during placebo runin Any other antidiabetic drug within 12 weeks prior to randomisation except metformin Acute coronary syndrome (nonSTEMI, STEMI unstable angina pectoris), stroke or transient ischemic attack within 12 weeks of informed consent Indication of liver disease Moderate to severe renal impairment Bariatric surgery within past 2 years Medical history of cancer or treatment for cancer within last 5 years Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell Contraindications hypersensitivity to concomitant drugs Treatment with antiobesity drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>